<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">


  <title>Multipotent all-trans-retinoic acid conjugate-crRASP</title>

  <meta property="og:type" content="website">
  <meta property="og:title" content="crRasp">
  <meta property="og:description" content="A novel all-trans-retinoic acid conjugate against Psoriasis, Acne, Acute Promyelotic Leukemia & Skin Cancer">
  <meta property="og:url" content="https://crrasp.eu">


  <link rel="icon" href="assets/images/favicon.ico">
  <link rel="stylesheet" href="/assets/css/style.css">
</head>

    
<body>
    <header id="home">
        
        <div class="container">
          <div class="header-image-container">
            <img class="header-image" src="assets/images/rasp.png" alt="crRASP Chemical formula">
          </div>
          <div class="header-content">
            <p>innovate with</p>
            <h1><b>crRASP</b></h1>
            <p>A novel all-trans-retinoic acid conjugate against</p>
      
            <div class="fragments">
              <div id="fragment1">Psoriasis</div>
              <div id="fragment2">Acne</div>
              <div id="fragment3">Other skin diseases</div>
              <div id="fragment4">Skin Cancers</div>
              <div id="fragment5">Acute Promyelotic Leukemia</div>
            </div>
          </div>
          <div class="banner">
            <p>Now in Pre-Clinical Evaluation Phase. Contact Us to Explore Investment Opportunities.</p>
            <a href="#contact-us" class="banner-cta">Sent us an email</a>
        </div>
        </div>



    </header>
    <main>

    <section id="biological-profile" class="biological-profile">
        <div class="container">
            <h2>Biological profile</h2>
            <p>crRASP is a multipotent conjugate of the naturally occurring all-trans-retinoic acid and the polyamine spermine that addresses the major challenges of current treatments:</p>
            <ul>
                <li class="list-item list-item-emphasized">not toxic or teratogenic</li>
                <li class="list-item list-item-emphasized">not irritant to skin and eyes</li>
                <li class="list-item list-item-emphasized">not phototoxic</li>
                <li class="list-item list-item-emphasized">not mutagenic</li>
                <li class="list-item list-item-emphasized">does not induce chromosome aberration</li>
            </ul>
        </div>
    </section>

    <section id="synthesis" class="synthesis">
        <div class="container">
            <h2>Synthesis</h2>
            <p>Two-step, high-yielding, fast & easy to perform at ambient temperature manfuacturing process:</p>
            <ul>
                <li class="list-item list-item-emphasized">Readily upscaled</li>
                <li class="list-item list-item-emphasized">Atom economic</li>
                <li class="list-item list-item-emphasized">Analytical grade(crRASP purity >98%)</li>
            </ul>

        </div>
    </section>
    <section id="intellectual-property" class="intellectual-property">
        <div class="container">
            <h2>Intellectual property</h2>
            <p>crRASP is a patented and secured compound:</p>
            <ul>
                <li class="list-item">Crystalline Forms for salts of N1,N12-DI(all-trans-retinoyl)spermine, Processes for their production and pharmaceutical compositions thereof.
                    <br><a href="https://data.epo.org/publication-server/document?iDocId=6638572" target="_blank">EP3878840A1/15-09-2021</a>
                        <span style="font-weight: bold;">Patent pending.</span>
                </li>
                <li class="list-item">Κρυσταλλικές μορφές της Ν1,Ν12-δι(all-trans-ρετινοϋλο)σπερμίνης, διεργασίες για την παραγωγής τους και φαρμακευτικές συνθέσεις αυτών.
                    <br>GR20200100131/10-03-2020<span style="font-weight: bold;">Patent granted.</span>
                </li>
        </div>
    </section>
    <section id="scientific-evidence" class="scientific-evidence">
        <div class="container">
            <h2>Scientific evidence</h2>
            <ul>
                <li class="list-item">RASP, administered orally at 50 mg/Kg to rats over two generations, showed no adverse effects on growth, characteristics, reflexes, or organ health[1].</li>
                <li class="list-item">In a comparative in vivo study, RASP showed four times more potent anti-inflammatory effects on rat paw oedema compared to tretinoin[2].</li>
                <li class="list-item">In an in vitro study, it was observed that RASP exhibited potent inhibitory effects on lipoxygenase, the crucial components of a biochemical pathway with a significant involvement in inflammation and immune response[2].</li>
                <li class="list-item">RASP significantly inhibits the production of IL-2 and IFN-γ by CD4+ and CD8+ cells, in contrast to the presently available retinoids, including tretinoin, and their isomers or esters. This suggests that RASP may have potential as an immunosuppressant drug[3].</li>
                <li class="list-item">Both tretinoin and RASP dose-dependently inhibited angiogenesis in the chicken embryo chorioallantoic membrane model, but RASP was more effective and could be used in a wider dose range due to lower toxicity compared with Tretinoin[4].</li>
                <li class="list-item">Both tretinoin and RASP decreased the number of HUVEC and prostate cancer cells in a dose-dependent manner. RASP was less cytotoxic than tretinoin on HUVEC cells, but more effective and potent on prostate cancer cells[4].</li>
                <li class="list-item">RASP inhibits RNase P, a key enzyme in protein synthesis at lower concentrations than retinoids. This suggests that RASP may be a more effective treatment for skin conditions that require increased protein synthesis such as psoriasis[5].</li>
                <li class="list-item">RASP has been shown to be effective against cancer. It works by regulating the expression of genes and miRNAs that are involved in apoptosis and the cell cycle[6].</li>
            </ul>
        </div>
    </section>
    <section id="research-publications" class="research-publications">
        <div class="container">
            <h2>Research Publications</h2>
            <ol>
                <li class="list-item">Petridis T., Giannakopoulou D., Stamatopoulou V., Grafanaki K., Kostopoulos C.G., Papadaki H., Malavaki C.J., Karamanos N.K., Douroumi S., Papachristou D., Magoulas G.E., Papaioannou D., Drainas D. “Investigation on Toxicity and Teratogenicity in Rats of a Retinoid-Polyamine Conjugate with Potent Anti-Inflammatory Properties”. Birth Defects Research (Part B) 107 (2016) 32-44.</li>
                <li class="list-item">Hadjipavlou-Litina D., Magoulas G.E., Bariamis S.E., Drainas D., Avgoustakis K., Papaioannou D. “Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?” Bioorganic &amp; Medicinal Chemistry 18 (2010) 8204-8217.</li>
                <li class="list-item">Papaioannou D., Drainas D., Tsambaos D., WO 2004/018001 A1; US 7,517,913 B2</li>
                <li class="list-item">Vourtsis D., Lamprou M., Sadikoglou E., Giannou A., Theodorakopoulou O., Sarrou E., Magoulas G.E., Bariamis S.E., Athanassopoulos C.M., Drainas D., Papaioannou D., Papadimitriou E. “Effect of an all-trans-retinoic acid conjugate with spermine on viability of human prostate cancer and endothelial cells in vitro and angiogenesis in vivo”. European Journal of Pharmacology 698 (2013) 122-130.</li> 
                <li class="list-item">Magoulas G., Papaioannou D., Papadimou E., Drainas D. “Preparation of spermine conjugates with acidic retinoids with potent ribonuclease P inhibitory activity: European Journal of Medicinal Chemistry 44 (2009) 2689-2695.</li>
                <li class="list-item">Grafanaki K., Skeparnias I., Kontos C.K., Anastasakis D., Korfiati A., Kyriakopoulos G., Theofilatos K., Mavroudi S., Magoulas G., Papaioannou D., Scorilas A., Stathopoulos C., Drainas D. “Pharmacoepigenomics circuits induced by a novel retinoid-polyamine conjugate in human immortalized keratinocytes” Pharmacogenomics J. 21 (2021) 638-648.</li>
            </ol>
        </div>
    </section>
    <section id="inventors" class="inventors">
        <div class="container">
            <h2>Inventors</h2>
            <ul>
                <li class="list-item">Dionysios Papaioannou, Emeritus Professor of Organic Chemistry
                    <br>Department of Chemistry, UNIVERSITY OF PATRAS<br>
                    dapapaio [at] upatras.gr
                    <a href="https://www.chem.upatras.gr/faculty/papaioannou" target="_blank">web</a>
                </li>
                <li class="list-item">Dionysios Drainas, Emeritus Professor of Biohemistry
                    <br>Department of Medicine, UNIVERSITY OF PATRAS<br>
                    drainas [at] upatras.gr
                    <a href="https://www.med.upatras.gr/en/department-of-biochemistry-and-biotechnology" target="_blank">web</a>
                </li>
                <li class="list-item">Konstantinos Avgoustakis, Professor of Organic Chemistry
                    <br>Department of Chemistry, UNIVERSITY OF PATRAS<br>
                    avgoust [at] upatras.gr
                    <a href="https://www.pharmacy.upatras.gr/index.php/el/staff/personell/professors/335-avgoustakis-konstantinos" target="_blank">web</a>
                </li>
            </ul>
        </div>
    </section>
    <section id="contact-us" class="contact-us">
        <div class="container">
            <h2>Do you have a question, a partnership or a licensing proposal?</h2>
            <h3>Please email us at:</h3>
            <p class="email-address">contact [at] crrasp [dot] eu</p>
        </div>
    </section>
    </main>
    <footer>
        <div class="container">
          <h2 class="grid-item header-grid-item"><b><a href="/#home">crRASP</a></b></h2>
          <p class="grid-item sitemap-grid-item">
            <a href="/#home">Home</a> · 
            <a href="/#biological-profile">Biological Profile</a> · 
            <a href="/#synthesis">Synthesis</a> · 
            <a href="/#intellectual-property">Intellectual Property</a> · 
            <a href="/#scientific-evidence">Scientific Evidence</a> · 
            <a href="/#research-publications">Research Publications</a> · 
            <a href="/#inventors">Inventors</a>
          </p>
          <small class="grid-item copyright-grid-item">
            &copy; Copyright 2023 crRASP inventors - All Rights Reserved
          </small>
        </div>
    </footer>

</body>
</html>